· The parties plan to conduct a clinical collaboration trial with Targovax TG
mutant RAS vaccine
· The collaboration will focus on testing TG vaccination in combination with
other treatments in late stage pancreatic cancer
Oslo, Norway, 15 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces that it has entered into an agreement with The Parker
Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute
(CRI) for a clinical collaboration with Targovax' TG mutant RAS vaccine (TG).
Under the agreement, PICI, CRI and Targovax plan to set up one or more clinical
trials with TG, in combination with other immuno-oncology treatments and
chemotherapy, in late stage pancreatic cancer. PICI will be the sponsor and
responsible for running the clinical trials and scientific analyses, CRI and
PICI co-organize the immunotherapy experts, and Targovax will be responsible for
TG supply. Targovax may also contribute by partial cost sharing of the trial(s).
The design of the first clinical trial is currently under discussion.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.
Targovax's lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102's targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).
About the Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the world's leading
nonprofit organization dedicated exclusively to transforming cancer patient care
by advancing scientific efforts to develop new and effective immune system-based
strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided
by a world-renowned Scientific Advisory Council that includes four Nobel
laureates and 26 members of the National Academy of Sciences, CRI has invested
$384 million in support of research conducted by immunologists and tumor
immunologists at the world's leading medical centers and universities, and has
contributed to many of the key scientific advances that demonstrate the
potential for immunotherapy to change the face of cancer treatment. CRI's
clinical program, the Anna-Maria Kellen Clinical Accelerator, is a unique
academic-nonprofit-industry collaboration model that serves as an "incubator"
that delivers multi-center clinical trials for promising new immunotherapy
combinations. CRI's venture philanthropy fund supports clinical trials within
this program, which fosters a collaborative environment that enables scientists
to advance their most ambitious research ideas, and accelerates studies that one
group or company could not do alone.
About the Parker Institute
The California, USA, based Parker Institute for Cancer Immunotherapy brings
together the best scientists, clinicians and industry partners to build a
smarter and more coordinated cancer immunotherapy research effort. The Parker
Institute is an unprecedented collaboration between the country's leading
immunologists and cancer centers. The program started by providing institutional
support to six academic centers, including Memorial Sloan Kettering Cancer
Center, Stanford Medicine, the University of California, Los Angeles, the
University of California, San Francisco, the University of Pennsylvania and The
University of Texas MD Anderson Cancer Center. The institute also provides
programmatic support for top immunotherapy investigators, including a group of
researchers at Dana-Farber Cancer Institute, Robert Schreiber, PhD, of
Washington University School of Medicine in St. Louis, Nina Bhardwaj, MD, PhD,
of the Icahn School of Medicine at Mount Sinai, Philip Greenberg, MD, of the
Fred Hutchinson Cancer Research Center, and Stephen Forman, MD, of City of Hope.
The Parker Institute network also includes more than 40 industry and nonprofit
partners, more than 60 labs and more than 170 of the nation's top researchers
focused on treating the deadliest cancers. The goal is to accelerate the
development of breakthrough immune therapies capable of turning most cancers
into curable diseases. The institute was created through a $250 million grant
from The Parker Foundation.